Quick Answer
Acumen Pharmaceuticals, Inc. reported Diluted EPS of $2.00 per share (loss) for fiscal year 2025.
Acumen Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.00 | -17.0% |
| 2024 | -$1.71 | -58.3% |
| 2023 | -$1.08 | -1.9% |
| 2022 | -$1.06 | +78.9% |
| 2021 | -$5.02 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.44 | +12.0% | +35.3% |
| June 30, 2025 | -$0.68 | -100.0% | -41.7% |
| March 31, 2025 | -$0.48 | -92.0% | +4.0% |
| September 30, 2024 | -$0.50 | -108.3% | -47.1% |
| June 30, 2024 | -$0.34 | -21.4% | -36.0% |
| March 31, 2024 | -$0.25 | +10.7% | -4.2% |
| September 30, 2023 | -$0.24 | +7.7% | +14.3% |
| June 30, 2023 | -$0.28 | -12.0% | +0.0% |
- Acumen Pharmaceuticals, Inc. showed a decrease of -17.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Acumen Pharmaceuticals, Inc.’s diluted eps has grown by 60.2% (from $5.02 per share (loss) to $2.00 per share (loss)).
- The most recent figure is from Acumen Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: